Wermeling to Provide 2015 Foster Lecture
September 24, 2015
UK College of Pharmacy Professor Dan Wermeling has been selected to provide keynote remarks during the College’s third annual Dr. Thomas S. Foster Leadership Day. Dr. Wermeling’s lecture is entitled “’Living the Dream’ Through the Eyes of a Student.” The Foster Lecture will take place at noon on Friday, September 25 at the College.
The program is part of the College’s efforts to recognize the outstanding leadership and academic and research excellence of the late Thomas S. Foster. The lecture will be followed by an academic pharmacy panel, which will be moderated by Dr. Wermeling. A program and reception will take place in the BioPharm Complex Atrium at 2:30 p.m.
Dr. Wermeling is a UKCOP alumnus who also completed a two-year clinical pharmacy residency at UK HealthCare. Upon completion of his residency, he completed a drug development fellowship under Thomas S. Foster at the College. After a brief stint in pharmaceutical industry, Dr. Wermeling became an Assistant Research Professor and Director of the UK College of Pharmacy Drug Product Evaluation Unit, and Director of the UK Hospital Department of Pharmacy Investigational Drug Service. Since joining the faculty he has practiced at the UK Medical Center, taught courses in analgesic therapeutics, drug delivery, and clinical research methods. He has led multidisciplinary clinical research programs and projects with investigational drugs, and was co-founder of the Medical Center’s clinical trials office. Dr. Wermeling has an active interest in pharmaceutical development and has advanced university intellectual property and has considerable Food and Drug Administration (FDA) and pharmaceutical regulatory experience.
Dr. Wermeling examined whether medications used chronically for the treatment of alcoholism can be administered acutely to treat the craving and urges that lead to relapse. With a team of scientists from the Magnetic Resonance Imaging and Spectroscopy Center, Departments of Behavioral Medicine and Psychiatry, he has developed a novel test system utilizing functional MRI as a tool to study the rapidly absorbed medication’s effects on neuronal activation within regions of the brain recognized to sub-serve craving and urges to drink alcohol.
His latest research was a five-year NIDA funded program to develop naloxone nasal spray for the emergency treatment of opioid overdose in the pre-hospital setting. The human pilot study was completed by his colleague Val Adams. The study demonstrated that naloxone plasma levels after intranasal administration of a novel formulation are equivalent to plasma levels achieved from intramuscular and subcutaneous administration. A New Drug Application has been filed with the FDA.